Sodelglitazar

• CAT Number: I009545
• CAS Number: 447406-78-2
• Molecular Formula: C23H21F4NO3S2
• Molecular Weight: 499.54
• Purity: ≥95%
• Synonyms: Sodelglitazar; GSK-677954; GW677954.;2-(4-(((2-(2-Fluoro-4-(trifluoromethyl)phenyl)-4-methyl-1,3-thiazol-5-yl)methyl)sulfanyl)-2-methylphenoxy)-2-methylpropanoic acid
• Target: PPAR agonist
• Solubility: Soluble in DMSO
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: 2-[4-[[2-[2-fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methylsulfanyl]-2-methylphenoxy]-2-methylpropanoic acid
• InChI: InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
• InChIKey: ZUGQWAYOWCBWGM-UHFFFAOYSA-N
• SMILES: CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=C(C=C(C=C3)C(F)(F)F)F)C)OC(C)(C)C(=O)O

Sodelglitazar（Cat No.:I009545）is an experimental dual PPAR (peroxisome proliferator-activated receptor) agonist being researched for its potential in treating metabolic disorders such as type 2 diabetes and dyslipidemia. It activates both PPAR-alpha and PPAR-gamma receptors, which help regulate lipid and glucose metabolism, aiming to improve insulin sensitivity, reduce blood sugar levels, and manage cholesterol levels. Sodelglitazar has shown promise in preclinical and early clinical trials, but its safety, efficacy, and long-term effects are still under investigation. It is considered a potential treatment option for patients with metabolic syndrome.